

## 51-102F3 Material Change Report [F]

### Item 1 Name and Address of Company

Endocan Solutions Inc.  
14<sup>th</sup> Floor, 1040 West Georgia Street  
Vancouver, BC V6E 4H8

### Item 2 Date of Material Change

October 9, 2019

### Item 3 News Release

The news release dated October 9, 2019 was disseminated through Canada Stockwatch and Market News under section 7.1 of National Instrument 51-102.

### Item 4 Summary of Material Change

Please refer to attached news release.

### Item 5 Full Description of Material Change

#### 5.1 Full Description of Material Change

Please refer to attached news release.

#### 5.2 Disclosure for Restructuring Transactions

N/A

### Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

### Item 7 Omitted Information

N/A

### Item 8 Executive Officer

Bruce Clark, Chief Executive Officer

### Item 9 Date of Report

October 9, 2019

## ENDOCAN FILES AMENDED MD&A AND PROVIDES CORPORATE UPDATE

**Vancouver, B.C., October 9, 2019 – Endocan Solutions Inc.** (the “Company” or “Endocan”) Endocan announces that, as a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

In February 2019 the Company signed a non-binding letter of intent (“LOI”) with Hai Beverages Inc. for the Company to purchase all of the issued and outstanding voting shares in Monashee Medicinal MJ from Hai Beverages for \$1,750,000. In June 27, 2019 the Company decided to terminate the LOI, at no penalty to the Company, and will instead focus on other opportunities.

The Company has filed on SEDAR an amended MD&A for the period ended July 31, 2019.

### **About Endocan Solutions Inc.**

Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the CSE on December 6, 2016, was subsequently put under new management, and has recently undergone a name change and share consolidation. The Company has recently brought required filings up to date under National Instrument 51-102. The immediate objective is to recapitalize the Company and management intends to seek and secure a suitable business acquisition and re-qualify the Company to meet the listing requirements of the Exchange.

### **ON BEHALF OF ENDOCAN SOLUTIONS INC.**

(signed) “Bruce Clark”

Chief Executive Officer

**For further information, please contact:**

**Bruce Clark**

**604-401-8100**